MDT three-lens brief
Evidence-based stock research on MDT. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 11.8pp over 30 days. · Trading at 13% of its 52-week range — deep in the lower band.
- Trading at 13% of its 52-week range — deep in the lower band.
- Underperforming SPY by 11.8pp over 30 days.
- Analyst mean target $109.08 — 31% above current (25 analysts).
- Debt-to-equity of 57.1 — balance-sheet-heavy.
MDT closed at $83.32 (-0.56%) as of 2026-04-25. Market cap: $106.97B. P/E (trailing) 23.3. Positives: analyst mean target $109.08 — 31% above current (25 analysts).. Concerns: trading at 13% of its 52-week range — deep in the lower band.; underperforming SPY by 11.8pp over 30 days.. Last quarter: Revenue $9.02B, net income $1.14B, free cash flow $4.07B.
Why three lenses on MDT, not one.
A single reasoning model has blind spots it doesn’t know about. We examine MDTacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/MDT" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath MDT brief"></iframe>